Latest filingAug 31, 2026Most recent Form 4
MAZE
Maze Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$20.6M1 sells
Net open-market-$20.6M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period5transactions
- A · Grants / awards · dominant2 · 40%
- M · Option exercise2 · 40%
- S · Open-market sells1 · 20%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- CSBO · dominant3 · 60%
- Director2 · 40%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeDandekar AtulCommon Stock · Direct
26,250Aug 28, 2026
Johnson Paula AStock Option (Right to Buy) · Direct
36,000Aug 13, 2026
Kornowski SophieStock Option (Right to Buy) · Direct
36,000Aug 13, 2026
Dandekar AtulStock Option (Right to Buy) · Direct
14,143Aug 28, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- DA-$128.7k
- KS+$0
- JA+$0
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
MAZE transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| MAZE | Dandekar Atul | CSBO | exercise10b5-1 | 7.50k | $0 | M | 0.0% | 08/31 | 08/28 | |
| MAZE | Dandekar Atul | CSBO | sale10b5-1 | 7.50k | -$20.6M | S | 0.0% | 08/31 | 08/28 | |
| MAZE | Dandekar Atul | CSBO | exercise10b5-1 | 7.50k | $7.81M | M | 0.0% | 08/31 | 08/28 | |
| MAZE | Kornowski Sophie | DIR | grant | 36.0k | $0 | A | −5.1% | 08/17 | 08/13 | |
| MAZE | Johnson Paula A | DIR | grant | 36.0k | $0 | A | −5.1% | 08/17 | 08/13 |
Maze Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Maze Therapeutics, Inc.?
Dandekar Atul, Kornowski Sophie, Johnson Paula A.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Dandekar Atul reported a sale on Aug 28, 2026 valued at $20.6M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $206,823.75. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.